Eutilex’s ‘307’ CAR-T Treatment for Advanced Hepatocellular Carcinoma Selected as a New Support Target Project
[Medical News – Daily Post=By Kim Jung Il]
The Korea New Drug Development Foundation (KDDF) has chosen Eutilex’s CAR-T treatment for patients with advanced hepatocellular carcinoma, ‘307’, as the ‘3rd new support target project in 2023’. This project will receive research and development funding for two years.
According to Utilex, the formal contract for the KDDF support project has been completed after the project was selected in October of the previous year.
‘307’: Targeting GPC3 Cancer Antigen
The ‘307’ project targets the cancer antigen GPC3, which is specifically overexpressed in hepatocellular carcinoma without affecting normal liver cells. Additionally, it is a CAR-T treatment that improves CAR-T function and the tumor microenvironment by producing IL-18.
Prime Minister Jang Young-gyun, in charge of the ‘307’ project, emphasized the significance of this treatment, stating, “Hepatocellular carcinoma is a disease with low responsiveness to standard treatments and a very high medical need for which there are no suitable alternative medicines.” He added, “Research and development funds are also supported through this national project selection, allowing us to focus more on clinical trials for the treatment ‘307’.”
Phase 1 Clinical Trial Approval
It is worth noting that the phase 1 clinical trial design for CAR-T treatment Eutilex ‘307’ was approved in February.
[의학신문·일간보사=김정일 기자] Eutilex’s CAR-T treatment for patients with advanced hepatocellular carcinoma, ‘307’, has been selected as the ‘3rd new support target project in 2023’ hosted by the Korea New Drug Development Foundation (KDDF) and will receive research and development funding for two years.
Utilex announced on the 12th that a formal contract had been completed after being selected as a KDDF support project last October.
‘307’, chosen for the project, targets the cancer antigen GPC3 which is specifically overexpressed in hepatocellular carcinoma without affecting normal liver cells. Additionally, it is a CAR-T treatment that improves CAR-T function and the tumor microenvironment by producing IL-18.
Prime Minister Jang Young-gyun, who is in charge of the ‘307’ project, said, “Hepatocellular carcinoma is a disease with low responsiveness to standard treatments and a very high medical need for which there are no suitable alternative medicines.” He added, “Since research and development funds are also supported through this national project selection, CAR-T “We intend to focus more on clinical trials for the treatment ‘307,’” he said.
Meanwhile, a phase 1 clinical trial design for CAR-T treatment Eutilex ‘307’ was approved in February.
#Eutilex #KDDF #enter #agreement #support #solid #tumor #CART #treatment
